The whistleblowing drama behind Astellas’s suspension from the ABPI

Deborah Cohen; Shai Mulinari; Piotr  Ozieranski

doi:10.1136/bmj.l4353

The whistleblowing drama behind Astellas’s suspension from the ABPI

Deborah Cohen, Shai Mulinari, Piotr Ozieranski

Sociology

Research output: Contribution to journal › Letter

Abstract

The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act

Original language	English
Article number	1453
Journal	BMJ: British Medical Journal
Volume	366
DOIs	https://doi.org/10.1136/bmj.l4353
Publication status	Published - 2019 Jul 2

Subject classification (UKÄ)

Sociology (excluding Social Work, Social Anthropology, Demography and Criminology)
Health Care Service and Management, Health Policy and Services and Health Economy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmj.l4353

3 Article

Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
Mulinari, S., Davis, C. & Ozieranski, P., 2021 May 6, In: Journal of White Collar and Corporate Crime. 2, 2, p. 69-80
Research output: Contribution to journal › Article › peer-review

Open Access
File
146 Downloads (Pure)
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson, A., Davis, C. & Mulinari, S., 2016, In: PLoS Medicine. 13, 1, e1001945.
Research output: Contribution to journal › Article › peer-review

Open Access
File
695 Downloads (Pure)
Complaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation
Zetterqvist, A., Merlo, J. & Mulinari, S., 2015, In: PLoS Medicine. 12, 2, e1001785.
Research output: Contribution to journal › Article › peer-review

Open Access
File
492 Downloads (Pure)

1 Finished

What can be learnt from the new pharmaceutical industry payment disclosures? A network and policy analysis of ties between companies and health professionals and organisations
Mulinari, S. (PI), Ozieranski, P. (CoI) & King, L. (CoI)
Swedish Council for Working Life and Social Research (Forte)
2017/01/01 → 2021/12/31
Project: Research

Cite this

@article{72e40f79030c426c94eed690ef123645,

title = "The whistleblowing drama behind Astellas{\textquoteright}s suspension from the ABPI",

abstract = "The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act",

author = "Deborah Cohen and Shai Mulinari and Piotr Ozieranski",

year = "2019",

month = jul,

day = "2",

doi = "10.1136/bmj.l4353",

language = "English",

volume = "366",

journal = "BMJ: British Medical Journal",

issn = "1756-1833",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - The whistleblowing drama behind Astellas’s suspension from the ABPI

AU - Cohen, Deborah

AU - Mulinari, Shai

AU - Ozieranski, Piotr

PY - 2019/7/2

Y1 - 2019/7/2

N2 - The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act

AB - The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act

U2 - 10.1136/bmj.l4353

DO - 10.1136/bmj.l4353

M3 - Letter

C2 - 31266743

SN - 1756-1833

VL - 366

JO - BMJ: British Medical Journal

JF - BMJ: British Medical Journal

M1 - 1453

ER -

The whistleblowing drama behind Astellas’s suspension from the ABPI

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.

Complaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation

Projects

What can be learnt from the new pharmaceutical industry payment disclosures? A network and policy analysis of ties between companies and health professionals and organisations

Cite this